INDUCING A TARGETED T-CELL RESPONSE TO VIRUSES AND CANCERS

A CLINICAL-STAGE IMMUNOTHERAPEUTICS COMPANY DEVELOPING A VACCINE PLATFORM FOR ANTIVIRAL & INDIVIDUALIZED CANCER THERAPY